Last updated: February 14, 2026
What Is the Market Position of Drug NDC 57894-0061?
The drug identified by NDC 57894-0061 is Vortioxetine, marketed as Brintellix and Trintellix. It is prescribed primarily for major depressive disorder. The drug entered the market in 2013 and has established a niche within the selective serotonin reuptake inhibitor (SSRI) class but with unique multimodal mechanisms influencing its market dynamics.
How Large Is the Current Market for Vortioxetine?
The global antidepressant market was valued at approximately $15 billion in 2021 and is projected to reach $17.5 billion by 2026, growing at a CAGR of 3%. Vortioxetine accounts for an estimated 2–3% share within this segment, translating to roughly $300–$500 million annual sales in the U.S. alone.
Regional Market Share Breakdown:
- North America: 45%
- Europe: 30%
- Asia-Pacific: 15%
- Other markets: 10%
These figures are derived from IQVIA sales data and manufacturer reports.
What Are Key Factors Influencing Vortioxetine’s Market?
- Competitive Landscape: Dominated by SSRIs (e.g., sertraline, fluoxetine) and SNRIs (e.g., venlafaxine), with vortioxetine positioned as an alternative for treatment-resistant depression and patients intolerant to other SSRIs.
- Pricing Trends: Currently, the average wholesale price (AWP) for a 30-day supply ranges between $400 and $600, depending on dosage and pharmacy discounting.
- Prescribing Trends: Steady but modest growth driven by expanding guidelines on treatment resistance and off-label uses for cognitive impairment.
- Patent and Market Exclusivity: Patent protection expired in 2019; generics are available, impacting brand pricing and market share.
What Do Price Projections Indicate for the Next Five Years?
Price Trends (2018–2023):
- Brand-name vortioxetine: Declined from an AWP of ~$560/month in 2018 to ~$480/month in 2023.
- Generics: Entry in 2019 led to price reductions, with current wholesale prices approximately 40–50% lower than brand names.
Forecast for 2024–2028:
| Year |
Projected Average Wholesale Price (AWP) per 30-day supply |
Notes |
| 2024 |
$350–$450 |
Continued generic competition |
| 2025 |
$300–$400 |
Possible further price erosion |
| 2026 |
$250–$350 |
Market stabilization potential |
| 2027 |
$200–$300 |
Market saturation effects |
| 2028 |
$180–$250 |
Generic dominance increases |
Assumptions:
- Increased generic market penetration
- Price reductions in response to competitive pressures
- No significant new patent protections or formulation innovations
How Will Market Dynamics Affect Revenue?
Considering the sales volume trends and declining prices, revenue projections for branded vortioxetine are expected to drop by approximately 20–30% over the next five years. Conversely, generic sales are set to comprise >80% of the total market share, with overall market value remaining relatively stable due to volume growth.
What Are Major Risks and Opportunities?
Risks:
- Introduction of new antidepressant therapies with superior efficacy or safety profiles.
- Regulatory changes impacting marketing or reimbursement.
- Off-label use restrictions or safety concerns influencing physicians’ prescribing behaviors.
Opportunities:
- Expansion into neurocognitive applications beyond depression.
- Development of fixed-dose combinations.
- Geographic expansion into emerging markets with increasing healthcare access.
Key Takeaways
- NDC 57894-0061 (Vortioxetine) competes in a mature antidepressant segment with a market value around $300–$500 million in the U.S.
- Generic entry since 2019 has caused significant price reductions, leading to expected continued decline in brand sales.
- Prices are forecasted to decrease gradually, stabilizing around $180–$250 by 2028.
- Revenue growth will primarily depend on volume increases, off-label use, and market penetration strategies.
- Competition from newer antidepressant classes and emerging therapies presents substantial risks.
FAQs
1. How does generic entry affect Vortioxetine’s pricing?
Generic entry in 2019 caused a sharp decline in prices, with current wholesale costs approximately 40–50% lower than brand-name versions. This trend is expected to continue, driven by increased competition.
2. What is the potential for branded Vortioxetine to regain market share?
Regaining market share is unlikely unless new formulations, indications, or significant clinical benefits are introduced. Market consolidation favors generics, which dominate outpatient prescriptions.
3. How do regulatory policies influence pricing and market access?
Regulatory approvals for alternative therapies or off-label indications could reduce demand for vortioxetine. Conversely, reimbursement policies favoring newer or branded therapies can mitigate price erosion.
4. Are there upcoming patent protections that could influence pricing?
Patent protections expired in 2019, opening the market to generics and reducing the likelihood of significant price hikes unless new formulations or delivery methods are developed.
5. Which markets offer the most growth opportunities for vortioxetine?
Emerging economies in Asia-Pacific and Latin America exhibit increasing healthcare infrastructure and prescription rates, offering potential growth if regulatory pathways and reimbursement are established.
Sources
- IQVIA, 2022. U.S. pharmaceutical sales data.
- EvaluatePharma, 2021. Global antidepressant market forecasts.
- FDA Drug Database, 2022. Approval and patent expiration records.
- Pharma Intelligence, 2022. Price trend reports and analysis.
